Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Titre officiel

Phase II Trial of Atezolizumab in BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Sommaire:

Cet essai de phase II vise à évaluer dans quelle mesure l’atézolizumab est efficace pour traiter les patients atteints d’un cancer de la vessie sans envahissement musculaire qui a récidivé et qui n’a pas répondu à un traitement par le bacille de Calmette-Guérin (BCG). Les anticorps monoclonaux comme l’atézolizumab peuvent bloquer certaines protéines présentes dans les globules blancs et ainsi renforcer le système immunitaire tout en limitant la croissance de la tumeur.

Description de l'essai

Primary Outcome:

  • Complete response (CR) rate in the subset of patients with carcinoma in situ (CIS) based on biopsy
  • Event-free survival (EFS)
Secondary Outcome:
  • Event-free survival (EFS) in the Ta/T1 subset
  • Progression-free survival (PFS)
  • Cystectomy-free survival
  • Bladder cancer specific survival
  • Overall survival
  • Incidence of adverse events
PRIMARY OBJECTIVES:
I. To estimate complete response at 25 weeks after registration for those with a carcinoma in situ (CIS) component and to evaluate event-free survival at 18 months in patients with BCG-unresponsive high-risk non-muscle invasive bladder cancer (Ta/T1/CIS) treated with atezolizumab. SECONDARY OBJECTIVES:
I. To estimate event-free survival at 18 months for the subset of patients with papillary cancer (Ta/T1). II. To estimate progression-free survival, cystectomy-free survival, bladder cancer-specific survival, overall survival in all patients. ADDITIONAL OBJECTIVES:
I. To estimate the level of agreement between local and central pathology review in terms of recurrence (for all patients) and complete response (for the CIS subset). II. To identify markers that predict response to atezolizumab in the CIS population and that are associated with event-free survival (EFS) in patients with Ta/T1/CIS BCG-unresponsive non-muscle invasive bladder cancer. The following markers will be tested: IIIa. Expression of PD-L1 and CD8 by immunohistochemistry (IHC). IIIb. Expression of immune signatures by ribonucleic acid (RNA)-sequencing (RNA-seq). IIIc. Peripheral immune response by mass cytometry (CyTOF) and TruCulture. OUTLINE:

Patients receive atezolizumab intravenously (IV) over 60 minutes on day 1. Treatment repeats every 21 days for up to 17 cycles (51 weeks) in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 12 weeks for 2 years and then every 24 weeks for 3 years.

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer